Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Invested Capital (2016 - 2026)

Ironwood Pharmaceuticals' Invested Capital history spans 17 years, with the latest figure at -$62.2 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 79.37% to -$62.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$62.2 million, a 79.37% increase, with the full-year FY2025 number at -$62.2 million, up 79.37% from a year prior.
  • Invested Capital hit -$62.2 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$64.7 million in the prior quarter.
  • Over the last five years, Invested Capital for IRWD hit a ceiling of $1.6 billion in Q4 2023 and a floor of -$334.1 million in Q1 2025.
  • Historically, Invested Capital has averaged $246.0 million across 5 years, with a median of $24.0 million in 2021.
  • Biggest five-year swings in Invested Capital: surged 11667.84% in 2021 and later crashed 155.55% in 2025.
  • Tracing IRWD's Invested Capital over 5 years: stood at $722.8 million in 2021, then fell by 9.74% to $652.4 million in 2022, then skyrocketed by 138.32% to $1.6 billion in 2023, then crashed by 119.38% to -$301.3 million in 2024, then skyrocketed by 79.37% to -$62.2 million in 2025.
  • Business Quant data shows Invested Capital for IRWD at -$62.2 million in Q4 2025, -$64.7 million in Q3 2025, and -$108.8 million in Q2 2025.